348 related articles for article (PubMed ID: 25676019)
1. Metformin and metabolic diseases: a focus on hepatic aspects.
Zheng J; Woo SL; Hu X; Botchlett R; Chen L; Huo Y; Wu C
Front Med; 2015 Jun; 9(2):173-86. PubMed ID: 25676019
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
Basu R; Shah P; Basu A; Norby B; Dicke B; Chandramouli V; Cohen O; Landau BR; Rizza RA
Diabetes; 2008 Jan; 57(1):24-31. PubMed ID: 17914032
[TBL] [Abstract][Full Text] [Related]
3. Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect.
Saisho Y
Endocr Metab Immune Disord Drug Targets; 2015; 15(3):196-205. PubMed ID: 25772174
[TBL] [Abstract][Full Text] [Related]
4. Current understanding of metformin effect on the control of hyperglycemia in diabetes.
An H; He L
J Endocrinol; 2016 Mar; 228(3):R97-106. PubMed ID: 26743209
[TBL] [Abstract][Full Text] [Related]
5. Metformin-like antidiabetic, cardio-protective and non-glycemic effects of naringenin: Molecular and pharmacological insights.
Nyane NA; Tlaila TB; Malefane TG; Ndwandwe DE; Owira PMO
Eur J Pharmacol; 2017 May; 803():103-111. PubMed ID: 28322845
[TBL] [Abstract][Full Text] [Related]
6. Involvement of insulin resistance in the protective effect of metformin against alcoholic liver injury.
Zhu Z; Jiang Z; Zhou J; Zhou D; Wang W; Zhao C; Zhen Z; Nanji AA
Alcohol Clin Exp Res; 2014 Jun; 38(6):1510-9. PubMed ID: 24797033
[TBL] [Abstract][Full Text] [Related]
7. Endothelial function and dysfunction: Impact of metformin.
Nafisa A; Gray SG; Cao Y; Wang T; Xu S; Wattoo FH; Barras M; Cohen N; Kamato D; Little PJ
Pharmacol Ther; 2018 Dec; 192():150-162. PubMed ID: 30056057
[TBL] [Abstract][Full Text] [Related]
8. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP.
Kim YD; Park KG; Lee YS; Park YY; Kim DK; Nedumaran B; Jang WG; Cho WJ; Ha J; Lee IK; Lee CH; Choi HS
Diabetes; 2008 Feb; 57(2):306-14. PubMed ID: 17909097
[TBL] [Abstract][Full Text] [Related]
9. The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact.
Phielix E; Szendroedi J; Roden M
Trends Pharmacol Sci; 2011 Oct; 32(10):607-16. PubMed ID: 21824668
[TBL] [Abstract][Full Text] [Related]
10. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial.
Sofer E; Boaz M; Matas Z; Mashavi M; Shargorodsky M
Metabolism; 2011 Sep; 60(9):1278-84. PubMed ID: 21411114
[TBL] [Abstract][Full Text] [Related]
11. Metformin in cancer.
Mallik R; Chowdhury TA
Diabetes Res Clin Pract; 2018 Sep; 143():409-419. PubMed ID: 29807101
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate.
Forcheron F; Abdallah P; Basset A; del Carmine P; Haffar G; Beylot M
Obesity (Silver Spring); 2009 Jul; 17(7):1381-9. PubMed ID: 19553925
[TBL] [Abstract][Full Text] [Related]
13. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial.
Haukeland JW; Konopski Z; Eggesbø HB; von Volkmann HL; Raschpichler G; Bjøro K; Haaland T; Løberg EM; Birkeland K
Scand J Gastroenterol; 2009; 44(7):853-60. PubMed ID: 19811343
[TBL] [Abstract][Full Text] [Related]
14. Metformin reverses fatty liver disease in obese, leptin-deficient mice.
Lin HZ; Yang SQ; Chuckaree C; Kuhajda F; Ronnet G; Diehl AM
Nat Med; 2000 Sep; 6(9):998-1003. PubMed ID: 10973319
[TBL] [Abstract][Full Text] [Related]
15. Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5.
Caton PW; Nayuni NK; Kieswich J; Khan NQ; Yaqoob MM; Corder R
J Endocrinol; 2010 Apr; 205(1):97-106. PubMed ID: 20093281
[TBL] [Abstract][Full Text] [Related]
16. Ginsenoside Compound K suppresses the hepatic gluconeogenesis via activating adenosine-5'monophosphate kinase: A study in vitro and in vivo.
Wei S; Li W; Yu Y; Yao F; A L; Lan X; Guan F; Zhang M; Chen L
Life Sci; 2015 Oct; 139():8-15. PubMed ID: 26285176
[TBL] [Abstract][Full Text] [Related]
17. Anti-diabetic and anti-lipidemic effects of chlorogenic acid are mediated by ampk activation.
Ong KW; Hsu A; Tan BK
Biochem Pharmacol; 2013 May; 85(9):1341-51. PubMed ID: 23416115
[TBL] [Abstract][Full Text] [Related]
18. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin.
Shaw RJ; Lamia KA; Vasquez D; Koo SH; Bardeesy N; Depinho RA; Montminy M; Cantley LC
Science; 2005 Dec; 310(5754):1642-6. PubMed ID: 16308421
[TBL] [Abstract][Full Text] [Related]
19. Differential AMPK phosphorylation by glucagon and metformin regulates insulin signaling in human hepatic cells.
Aw DK; Sinha RA; Xie SY; Yen PM
Biochem Biophys Res Commun; 2014 May; 447(4):569-73. PubMed ID: 24735537
[TBL] [Abstract][Full Text] [Related]
20. Relative contribution of glycogenolysis and gluconeogenesis to hepatic glucose production in control and diabetic rats. A re-examination in the presence of euglycaemia.
Giaccari A; Morviducci L; Pastore L; Zorretta D; Sbraccia P; Maroccia E; Buongiorno A; Tamburrano G
Diabetologia; 1998 Mar; 41(3):307-14. PubMed ID: 9541171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
